FI870981A - Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. - Google Patents

Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. Download PDF

Info

Publication number
FI870981A
FI870981A FI870981A FI870981A FI870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A
Authority
FI
Finland
Prior art keywords
ricintoxin
producerats
mikrobisk
kedja
rekombinant
Prior art date
Application number
FI870981A
Other languages
English (en)
Other versions
FI870981A0 (fi
Inventor
Robert Ferris
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of FI870981A0 publication Critical patent/FI870981A0/fi
Publication of FI870981A publication Critical patent/FI870981A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI870981A 1986-03-06 1987-03-05 Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. FI870981A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83684886A 1986-03-06 1986-03-06
US06/905,283 US4689401A (en) 1986-03-06 1986-09-09 Method of recovering microbially produced recombinant ricin toxin a chain

Publications (2)

Publication Number Publication Date
FI870981A0 FI870981A0 (fi) 1987-03-05
FI870981A true FI870981A (fi) 1987-09-07

Family

ID=27125896

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870981A FI870981A (fi) 1986-03-06 1987-03-05 Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik.

Country Status (7)

Country Link
US (1) US4689401A (fi)
EP (1) EP0237297A1 (fi)
AU (1) AU596153B2 (fi)
CA (1) CA1308680C (fi)
DK (1) DK118887A (fi)
FI (1) FI870981A (fi)
NO (1) NO870668L (fi)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US4956453A (en) * 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
IL80972A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
WO1989000583A1 (en) * 1987-07-17 1989-01-26 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
WO1989004839A1 (en) * 1987-11-24 1989-06-01 Genetics Institute, Inc. Improved ricin molecules and ricin toxin conjugates
GB2253210B (en) * 1991-02-26 1995-06-07 Ici Plc Soluble heterologous polypeptide produced by culture of recombinant microorganisms
USH1985H1 (en) 1992-01-09 2001-08-07 The United States Of America As Represented By The Secretary Of The Navy Method for detecting biological toxins
US5453271A (en) * 1993-06-28 1995-09-26 The United States Of America As Represented By The Secretary Of The Army Vaccine against ricin toxin
US5437986A (en) * 1994-06-22 1995-08-01 Schering Corporation Extraction of heterologous insoluble proteins from bacteria
CA2374398C (en) 1999-05-27 2011-03-15 Ira Pastan Immunoconjugates having high binding affinity
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
WO2005052006A2 (en) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
CN101977932B (zh) 2008-01-31 2014-09-03 美国政府健康及人类服务部 工程化抗体恒定结构域分子
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
ES2695899T3 (es) 2010-06-16 2019-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Anticuerpos contra endoplasmina y su uso
EP3797847A1 (en) 2010-07-30 2021-03-31 Medlmmune, LLC Purified active polypeptides or immunoconjugates
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
JP6216317B2 (ja) 2011-09-09 2017-10-18 メディミューン リミテッド 抗Ｓｉｇｌｅｃ−１５抗体およびその使用
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
CN104520331B (zh) 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
US9920124B2 (en) 2012-12-20 2018-03-20 Medimmune, Llc Methods of producing immunoconjugates
WO2015054691A2 (en) 2013-10-11 2015-04-16 The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN106999578B (zh) 2014-07-31 2022-03-04 美国政府(由卫生和人类服务部的部长所代表) 针对epha4的人类单克隆抗体和其用途
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
US10421810B2 (en) 2015-10-09 2019-09-24 Lentigen Technology, Inc. Chimeric antigen receptors and methods of use
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
CN109843922B (zh) 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
US10183993B2 (en) 2017-01-09 2019-01-22 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
CA3057838A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
AU2018268970A1 (en) 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
JP7237926B2 (ja) 2017-07-31 2023-03-13 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法
AU2018331517A1 (en) 2017-09-15 2020-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
CA3078962A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
JP7377802B2 (ja) 2017-12-20 2023-11-10 レンティジェン・テクノロジー・インコーポレイテッド 免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
US11939377B2 (en) 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
US10844128B2 (en) 2018-09-20 2020-11-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
WO2020069184A2 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2020113108A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
AU2020232789A1 (en) 2019-03-06 2021-10-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
CN114364801B (zh) 2019-05-30 2024-04-19 莱蒂恩技术公司 用于用抗bcma免疫治疗来治疗癌症的组合物和方法
CN114269783B (zh) 2019-07-02 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 结合egfrviii的单克隆抗体及其应用
WO2021081052A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
AU2021296423A1 (en) 2020-06-22 2023-02-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
JP2023548555A (ja) 2020-11-05 2023-11-17 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
EP4352099A1 (en) 2021-06-09 2024-04-17 The United States of America, as represented by The Secretary, Department of Health and Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
WO2024044743A1 (en) 2022-08-26 2024-02-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
GR79124B (fi) * 1982-12-22 1984-10-02 Genentech Inc
DE3584486D1 (de) * 1984-02-08 1991-11-28 Cetus Corp Toxinkonjugate.
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1286843C (en) * 1985-10-30 1991-07-23 Leo S. Lin Purification method for proteins
AU601956B2 (en) * 1986-03-07 1990-09-27 Cetus Corporation Recombinant ricin toxin

Also Published As

Publication number Publication date
NO870668D0 (no) 1987-02-19
US4689401A (en) 1987-08-25
NO870668L (no) 1987-09-07
AU6973887A (en) 1987-09-10
DK118887D0 (da) 1987-03-06
AU596153B2 (en) 1990-04-26
CA1308680C (en) 1992-10-13
FI870981A0 (fi) 1987-03-05
EP0237297A1 (en) 1987-09-16
DK118887A (da) 1987-09-07

Similar Documents

Publication Publication Date Title
FI870981A0 (fi) Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik.
FI873897A0 (fi) Maenniskans erytropoietin som framstaellts medelst rekombinations-dna-teknik.
FI86241B (fi) Foerfarande foer oeverfoering av bildsignaler med hjaelp av transformationskodning.
FI853309L (fi) Foerfarande foer behandling av taender med speciella ljuspolymeriserade blandningar som innehaoller en acylfosfinoxid omfattande katalyt.
FI871872A (fi) Logik foer minskning av hastigheten foer vindturbin med reglerbar stigning.
FI873054A0 (fi) Hydroformylering som utnyttjar litet flyktiga fosfinligander loesliga i organiska aemnen.
FI884924A (fi) Humanimmuglobulin som producerats med hybrid-dna-teknik.
FI861396A (fi) Braedparkett som isolerar stegljudet.
FI864649A (fi) Short-dwell-bestrykningsanordning foer bestrykning av en materialbana med bestrykningsmassa.
FI874375A0 (fi) Flerskedesfoeraongare med en foeraongande kondensator som vaetskefoeraongningsskede.
FI874465A0 (fi) Uppvaermningsanordning som anvaender mikrovaogsenergi.
FI870043A0 (fi) Foerfarande foer laddning av uppaotgaoende borrhaol med flytbara explosiva aemnen.
FI864835A0 (fi) Kaerllock som foerhindrar inaotdragning.
FI865312A (fi) Anvaendning av esterfoerening som temporaer mikrobicid.
FI864526A0 (fi) Foerfarande foer tillvaratagande av vaerme i samband med en gasturbinprocess.
FI871174A0 (fi) Foerfarande foer bestaemning av haptener med hjaelp av immunoanalysteknik.
FI872249A (fi) Foerfarande foer framstaellning av foereningar som inhiberar dopamin- -hydroxylas.
FI873320A0 (fi) Telekommunikationscentralutrustning med flerpartsledningar som anvaender isdn-teknik.
FI870724A0 (fi) Kraftanlaeggning med renare av centrifugaltyp foer foerbraenningsgaser.
FI873994A (fi) Foerfarande foer daempning av nedsmutsning som foerorsakats av olefinfoereningar innehaollande kolvaetekompositioner.
FI861833A0 (fi) Anordning foer maetning av kraften som paoverkar en lyftkrok.
FI923164A (fi) Foereningar anvaendbara som mellan- produkter.
FI865175A0 (fi) Specialmatta som glidyta.
FI861519A0 (fi) Lakutrustning som lossas hydrauliskt.
FI860363A0 (fi) Foerfarande foer formning av metall- och metallfoereningsbelaeggningar med hjaelp av kemisk gasfasbelaeggning.

Legal Events

Date Code Title Description
FD Application lapsed
BB Publication of examined application
CD Patent refused following opposition
FD Application lapsed

Owner name: CETUS ONCOLOGY CORPORATION